Paratek pharmaceuticals announces positive top-line data from phase 2b study of oral omadacycline (omc) in nontuberculous mycobacterial (ntm) abscessus pulmonary disease

First randomized placebo-controlled trial in ntm abscessus symptom-based endpoints showed favorable improvement in frequency and severity of the most common symptoms microbiologic endpoints showed higher conversion to negative sputum culture, without emergence of resistance to omadacycline in this 12-week study, omadacycline appeared to be safe and well-tolerated with no new or unexpected safety signals boston, nov. 08, 2024 (globe newswire) -- paratek pharmaceuticals, inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for serious diseases, today announced top-line results from its phase 2b study of oral omadacycline in adult patients with nontuberculous mycobacterial (ntm) pulmonary disease caused by mycobacterium abscessus complex (mabc). “the results from this first-ever placebo-controlled trial in mabc patients are exciting and support the idea that omadacycline has clinical utility in this very challenging disease setting.
OMC Ratings Summary
OMC Quant Ranking